Both GTx Inc. (NASDAQ:GTXI) and XBiotech Inc. (NASDAQ:XBIT) are each other’s competitor in the Biotechnology industry. Thus the compare of their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
In table 1 we can see GTx Inc. and XBiotech Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 shows us GTx Inc. and XBiotech Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
GTx Inc. is 156.00% more volatile than Standard and Poor’s 500 because the company has a beta of 2.56. Competitively, XBiotech Inc.’s beta is 0.31 which is 69.00% less volatile than Standard and Poor’s 500.
GTx Inc. has a Current Ratio of 4.3 and a Quick Ratio of 4.3. Competitively, XBiotech Inc.’s Current Ratio is 9.3 and has 9.3 Quick Ratio. XBiotech Inc.’s better ability to pay short and long-term obligations than GTx Inc.
The table given features the ratings and recommendations for GTx Inc. and XBiotech Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
$17 is GTx Inc.’s average target price while its potential upside is 1,600.17%.
Institutional and Insider Ownership
GTx Inc. and XBiotech Inc. has shares held by institutional investors as follows: 22.5% and 13.2%. GTx Inc.’s share held by insiders are 17.8%. Insiders Competitively, held 37.5% of XBiotech Inc. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
For the past year GTx Inc.’s stock price has smaller growth than XBiotech Inc.
On 6 of the 7 factors XBiotech Inc. beats GTx Inc.
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The companyÂ’s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.